Bio-Techne Financial Statements
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Bio-Techne revenue and earnings
In fiscal 2026, Bio-Techne generated $1.22 billion in revenue, down 0.4% from fiscal 2025, its first annual decline since 2013. Net income was $181.9 million (+147.8% year over year), for a net margin of 15.0% versus a median of 15.1% in the prior 5 years. Gross margin was 65.8% (up from 64.8%) and operating margin 20.7%.
Diluted earnings per share came in at $1.16, up from $0.46. Over the last 5 fiscal years, TECH's revenue has grown at a 5.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Techne income statement (annual)
| Fiscal year (USD) | FY 20262026-06-30 | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.22B | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | 714.01M | 642.99M | 563.00M |
| Revenue growth (YoY) | -0.38% | +5.23% | +1.97% | +2.81% | +18.75% | +26.04% | +3.46% | +11.04% | +14.21% | +12.82% |
| Cost of Revenue | 415.97M | 429.36M | 389.33M | 366.89M | 349.10M | 298.18M | 255.50M | 240.51M | 210.85M | 188.46M |
| Gross Profit | 799.07M | 790.27M | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | 473.49M | 432.14M | 374.54M |
| Operating Expenses | 547.18M | 688.02M | 563.04M | 470.87M | 459.91M | 395.55M | 325.77M | 326.77M | 295.96M | 253.96M |
| Research & Development | 94.77M | 99.50M | 96.66M | 92.49M | 87.14M | 70.60M | 65.19M | 62.41M | 55.33M | 53.51M |
| Selling, General & Admin | 452.42M | 588.52M | 466.38M | 378.38M | 372.77M | 324.95M | 260.58M | 264.36M | 240.64M | 200.44M |
| Operating Income | 251.89M | 102.25M | 206.69M | 298.94M | 296.59M | 237.30M | 157.42M | 146.72M | 136.18M | 120.58M |
| Interest Expense | 9.63M | 8.51M | 15.74M | 11.21M | 11.31M | 13.95M | 19.20M | 21.70M | 10.19M | 7.36M |
| Other Income (Expense) | -11.21M | -3.79M | -21.00M | 39.72M | 4.80M | -89.12M | 119.06M | -34.70M | -10.23M | -8.62M |
| Pretax Income | 240.68M | 98.46M | 185.69M | 338.66M | 301.39M | 148.18M | 276.48M | 112.02M | 125.95M | 111.96M |
| Income Tax | 58.82M | 25.06M | 17.58M | 53.22M | 38.29M | 8.59M | 47.18M | 15.94M | -198.00K | 35.88M |
| Net Income | 181.86M | 73.40M | 168.10M | 285.26M | 272.05M | 140.41M | 229.30M | 96.07M | 126.15M | 76.09M |
| Net Income growth (YoY) | +147.77% | -56.34% | -41.07% | +4.86% | +93.75% | -38.76% | +138.67% | -23.84% | +65.80% | -27.17% |
| EPS (Basic) | 1.17 | 0.47 | 1.07 | 1.81 | 1.73 | 0.91 | 6.00 | 2.54 | 3.36 | 2.04 |
| EPS (Diluted) | 1.16 | 0.46 | 1.05 | 1.76 | 1.66 | 0.87 | 5.82 | 2.47 | 3.31 | 2.03 |
| Shares Outstanding (Basic) | 155.96M | 157.52M | 157.71M | 157.18M | 156.87M | 154.99M | 38.20M | 37.78M | 37.48M | 37.31M |
| Shares Outstanding (Diluted) | 157.01M | 159.72M | 160.77M | 161.85M | 164.11M | 161.93M | 39.40M | 38.89M | 38.05M | 37.50M |
| EBITDA | 349.25M | 212.16M | 318.40M | 406.18M | 397.66M | 325.04M | 240.16M | 224.89M | 200.64M | 180.62M |
| Gross Margin | 65.77% | 64.80% | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% |
| Operating Margin | 20.73% | 8.38% | 17.83% | 26.30% | 26.83% | 25.49% | 21.31% | 20.55% | 21.18% | 21.42% |
| Net Margin | 14.97% | 6.02% | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.62% | 13.51% |
This table shows 10 annual periods of Bio-Techne's income statement, from FY 2026 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TECH's reporting calendar. What is a income statement?